Law360, New York (January 03, 2012, 8:49 PM ET) -- The Ninth Circuit on Friday upheld the dismissal of a proposed class action claiming biotechnology company InterMune Inc. fraudulently promoted its drug Actimmune as a remedy for a deadly lung disease it was not approved to treat.
A three-judge panel affirmed a California federal judge's September 2010 ruling that the plaintiffs — a proposed class of patients, as well as insurer Government Employees Health Association Inc. — had failed in their third attempt to bring actionable claims against InterMune, former CEO Dr. Scott Harkonen and Genentech...
9th Circ. Puts Lid On Actimmune Marketing Action
To view the full article, take a free trial now.
